University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK.
Arthritis Care Res (Hoboken). 2012 Jan;64(1):66-70. doi: 10.1002/acr.20553.
To ascertain whether bone mineral density loss during the first year of treatment for early rheumatoid arthritis (RA) as assessed by dual x-ray absorptiometry (DXA) is associated with long-term function, quality of life, and radiographic progression.
Early RA patients, prior to commencing disease-modifying antirheumatic drug therapy, underwent evaluation with DXA scans of both hands, femoral neck, and lumbar spine at the time of diagnosis, then at 1 year and final followup at >6 years. Clinical and laboratory data and hands and feet radiographs were obtained at baseline and final followup.
Sixty-four patients were assessed. At baseline, median disease duration was 6 months, mean 28-joint Disease Activity Score was 5.85, and median Health Assessment Questionnaire score was 1.38. Median followup was 6.4 years (range 5.1-7.2 years). For erosion scores, 86% of patients with hand bone density loss above the smallest detectable change after 1 year progressed versus 55% of those with no hand bone density loss (P = 0.006). However, baseline radiographs showed a similar strength of association. Eighty-four percent of patients with erosions at baseline had erosion progression versus 57% of those with no baseline erosions (P = 0.021). Additionally, first-year bone density loss was not associated with function and quality of life status at followup.
Hand bone loss during the first year of treatment in early RA, as assessed with DXA, was associated with a high likelihood of radiographic progression; however, in the current study this was not superior to baseline radiographs. Furthermore, it was not associated with patient-reported outcomes.
通过双能 X 线吸收法(DXA)评估,确定早期类风湿关节炎(RA)患者在治疗的第一年中骨密度的丢失是否与长期功能、生活质量和放射学进展有关。
在开始使用疾病修饰抗风湿药物治疗之前,早期 RA 患者在诊断时以及 1 年和 >6 年的最终随访时,进行双手、股骨颈和腰椎的 DXA 扫描评估。基线和最终随访时获得临床和实验室数据以及手和脚的 X 光片。
对 64 名患者进行了评估。基线时,疾病持续时间中位数为 6 个月,28 关节疾病活动评分均值为 5.85,健康评估问卷评分中位数为 1.38。中位随访时间为 6.4 年(范围 5.1-7.2 年)。对于侵蚀评分,在第 1 年骨密度损失超过最小可检测变化的患者中,86%的患者进展,而无手部骨密度损失的患者中,55%的患者进展(P = 0.006)。然而,基线 X 光片显示出类似的关联强度。基线时有侵蚀的患者中,84%的患者有侵蚀进展,而基线时无侵蚀的患者中,57%的患者有侵蚀进展(P = 0.021)。此外,在治疗的第一年中,DXA 评估的手部骨密度丢失与随访时的功能和生活质量状态无关。
早期 RA 患者在治疗的第一年中,通过 DXA 评估的手部骨丢失与放射学进展的高度可能性相关;然而,在本研究中,这并不优于基线 X 光片。此外,它与患者报告的结果无关。